

ASX Announcement/Press Release | 18 December 2023 AdAlta Limited (ASX:1AD)

AdAlta Launches New Investor Hub

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”) is pleased to announce the formal launch of its Investor Hub. The Investor Hub is a dedicated platform for investors to learn more about, and interact with, AdAlta.

The new Investor Hub enables the Company to enhance and augment traditional content including ASX and media releases with videos accompanying select announcements, interviews, research and other educational material.

Most significantly, the Investor Hub Q&A function enables investors to post questions and feedback to AdAlta and receive a response from the Company. AdAlta encourages commentary on specific announcements and general Company matters.

AdAlta CEO and Managing Director, Tim Oldham said: "We are excited to utilise this new investor hub to increase our ability to interact and engage with our investor base. We hope all of our investors will take the opportunity to ask us questions directly and learn more about AdAlta and look forward to deeper and more real time conversations with our community."

Visit the AdAlta Investor Hub here: <https://investorhub.adalta.com.au/>

How to join the AdAlta Investor Hub

1. Head to <https://investorhub.adalta.com.au/auth/signup> or scan the QR code below with your smartphone device and this will take you to the AdAlta Investor Hub sign-up page:



2. Follow the prompts to sign up for an Investor Hub account

3. Complete your account profile

Existing subscribers to AdAlta's email distributions

Investors who have previously signed up for our email distributions will continue to receive them. To access all the features of the new Investor Hub they will still need to sign up for an Investor Hub account and are encouraged to do so.

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.


AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by internally discovering and developing selected i-body® enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

To learn more, please visit: www.adalta.com.au

 Follow us on [Twitter](#)

 Follow us on [LinkedIn](#)

This ASX announcement has been authorised by the Board of AdAlta Limited (ASX:1AD)